Lilly says its obesity drugs helped patients lose weight in clinical trials
LLY•Eli Lilly said its investigational EloraTZP combination produced average weight loss of up to 23.3% at 48 weeks in a Phase 2 trial, while Zepbound reduced adolescents’ BMI by an average of 21.4% at 72 weeks in Phase 3 trials.
1. Trial results
In a Phase 2 trial of EloraTZP, an investigational combination of eloralintide and tirzepatide, overweight or obese adults with type 2 diabetes lost up to an average of 23.3% of their weight at 48 weeks. Lilly said up to 60% no longer met the BMI criteria for obesity. A1C fell by up to an average of 2.9%, and up to 77% of participants achieved normal blood sugar levels.
2. Adolescent trials
In Phase 3 SURMOUNT-ADOLESCENTS trials, Zepbound reduced BMI by an average of 21.4% at 72 weeks among adolescents aged 12 to 18 with obesity. More than half no longer met the BMI criteria for obesity, and participants reported improvements in weight-related quality of life, including physical comfort and body esteem.
